The efficacy of delafloxacin was noninferior compared with moxifloxacin for treatment of community-aquired bacterial pneumonia (CABP) in patients with diabetes. The results of this study was presented at ID Week 2019, held October 2 to October 6, 2019, in Washington, DC.

Adults with CABP with at least 2 presenting symptoms were randomly assigned in a 1:1 ratio to treatment with either delafloxacin or moxifloxacin for 5 to 10 days. Patients received a minimum of 3 days of intravenous treatment followed by oral treatment for the remaining days. Clinical success was defined as a complete or near resolution of signs and symptoms and no further antibiotics needed.

A total of 131 patients were included in the study; 59% were male and the mean age was 66 years. Bacterial pathogens were identified in 59% of patients at baseline. Patients received treatment for approximately 8.5 days, and results showed that early clinical response occurred in 90% of patients with diabetes who received delafloxacin compared with 88.5% of those who received moxifloxacin. Further, clinical success at test of cure was 87.1% in patients who received delafloxacin vs 86.9% of those who received moxifloxacin.

A total of 18.6% taking delafloxacin and 11.7% taking moxifloxacin had at least 1 treatment-related adverse event, the most common being gastrointestinal-related. A total of 3 delafloxacin and 2 moxifloxacin patients died during the study, though investigators reported this was unrelated to treatment. No patients experienced hypoglycemia

Related Articles

“[Delafloxacin] appears effective and well tolerated in patients with diabetes and CABP,” the authors concluded.  

Follow @EndoAdvisor

Reference

Kaidashev I, Nitu M, Popescu M, et al. Treatment of community acquired bacterial pneumonia (CABP) in patients with diabetes: outcomes from a global phase 3 study of selafloxacin (DLX). Presented at: IDWeek 2019; October 2-6, 2019; Washington DC. Poster 222.

This article originally appeared on Infectious Disease Advisor